NeoGenomics, Inc. (NEO) has a negative trailing P/E of -1.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 50.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -53.15%, forward earnings yield 1.98%. PEG 1.07.
Criteria proven by this page:
Overall SharesGrow Score: 50/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -21.9 | -0.25 | 0.72 | 0.55 | - |
| 2017 | -355.4 | 3.80 | 0.68 | 0.59 | - |
| 2018 | 87.5 | -0.13 | 0.72 | 0.83 | - |
| 2019 | 73.4 | 0.42 | 1.16 | 1.44 | - |
| 2020 | 280.2 | -5.41 | 1.68 | 2.63 | 0.74% |
| 2021 | -98.1 | 0.35 | 0.74 | 1.69 | - |
| 2022 | -1.6 | 0.00 | 0.23 | 0.45 | - |
| 2023 | -4.6 | 0.12 | 0.43 | 0.69 | - |
| 2024 | -5.3 | 0.46 | 0.46 | 0.63 | - |
| 2025 | -2.8 | -0.08 | 0.36 | 0.41 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.39 | $244.08M | $-6.14M | -2.5% |
| 2017 | $-0.14 | $240.25M | $-396K | -0.2% |
| 2018 | $0.14 | $276.74M | $2.64M | 1% |
| 2019 | $0.39 | $408.83M | $8.01M | 2% |
| 2020 | $0.19 | $444.45M | $4.17M | 0.9% |
| 2021 | $-0.35 | $484.33M | $-8.35M | -1.7% |
| 2022 | $-5.80 | $509.73M | $-144.25M | -28.3% |
| 2023 | $-3.50 | $591.64M | $-87.97M | -14.9% |
| 2024 | $-3.10 | $660.57M | $-78.73M | -11.9% |
| 2025 | $-4.20 | $727.33M | $-108.03M | -14.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.17 | $0.10 – $0.22 | $796.68M | $794.8M – $797.3M | 8 |
| 2027 | $0.31 | $0.21 – $0.37 | $874.21M | $869.05M – $882.86M | 8 |
| 2028 | $0.44 | $0.43 – $0.46 | $953.86M | $951.96M – $955.75M | 2 |
| 2029 | $0.62 | $0.62 – $0.62 | $1.03B | $1.02B – $1.03B | 1 |
| 2030 | $0.81 | $0.80 – $0.82 | $1.11B | $1.1B – $1.11B | 1 |
